{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:02Z","timestamp":1790697902730,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK062708"],"award-info":[{"award-number":["DK062708"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007827","name":"American College of Gastroenterology","doi-asserted-by":"publisher","award":["ACG\u2010FDA Visiting Fellowship Program"],"award-info":[{"award-number":["ACG\u2010FDA Visiting Fellowship Program"]}],"id":[{"id":"10.13039\/100007827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatosplenic T\u2010cell lymphoma (HSTCL) is a rare, poorly treatable malignancy associated with therapy for IBD. Current knowledge of HSTCL risk in IBD comes from an era of step\u2010up therapy, before earlier use of biologics or combination therapy was advocated to achieve deep mucosal healing. HSTCL risk among newer biologic classes has also not been evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To systematically characterise the association of HSTCL with biologic therapy for IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a literature search and query of the Food and Drug Administration Adverse Event Reporting System to summarise HSTCL cases among IBD patients with prior biologic exposure. Demographics and immunosuppression exposure were extracted. Patients were stratified by current regimen (combination therapy, biologic monotherapy or no biologic), and biologic class (anti\u2010TNF, anti\u2010integrin, anti\u2010interleukin 12\/23).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty\u2010two cases of HSTCL were identified from 2486 abstracts and 181 FDA Adverse Events Reporting System reports. The median age of affected patients was 28\u00a0years (range 12\u201081), and 83.6% were male, 84.7% had Crohn's disease. Five of 62 patients had no reported azathioprine\/mercaptopurine exposure. Three patients within the cohort developed HSTCL after exposure to natalizumab, vedolizumab or ustekinumab; all three also had anti\u2010TNF and azathioprine\/mercaptopurine exposure. Forty\u2010three of 49 (87.8%) patients with known outcomes died with a median survival of 5\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Consistent with existing data, almost all identified HSTCL cases among IBD patients on biologic therapy had azathioprine\/mercaptopurine exposure, and all cases on patients exposed to biologics had anti\u2010TNF exposure. These data suggest initiating a patient\u2010centred discussion before starting anti\u2010TNF therapy or other biologics.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.15637","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T20:27:31Z","timestamp":1580243251000},"page":"527-533","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Systematic review: hepatosplenic T\u2010cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3611-8628","authenticated-orcid":false,"given":"Eric D.","family":"Shah","sequence":"first","affiliation":[{"name":"Section of Gastroenterology and Hepatology Dartmouth\u2010Hitchcock Medical Center Lebanon NH USA"},{"name":"Division of Gastroenterology and Hepatology Michigan Medicine Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot S.","family":"Coburn","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology Dartmouth\u2010Hitchcock Medical Center Lebanon NH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Nayyar","sequence":"additional","affiliation":[{"name":"Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry Jo","family":"Lee","sequence":"additional","affiliation":[{"name":"Food and Drug Administration Silver Spring MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna L.","family":"Koliani\u2010Pace","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology Dartmouth\u2010Hitchcock Medical Center Lebanon NH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology Dartmouth\u2010Hitchcock Medical Center Lebanon NH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.01.005"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.05.006"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802455867"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.09.016"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.449"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181957a11"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.056"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.052"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.569"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.54"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.055"},{"key":"e_1_2_7_17_1","unstructured":"Groupe d\u2019Etude Therapeutique des Affections Inflammatoires Digestives.A proSpective Randomized Controlled Trial comParing infliximAb\u2010antimetabolites Combination Therapy to Anti\u2010metabolites monotheRapy and Infliximab monothErapy in Crohn\u2019s Disease Patients in Sustained Steroid\u2010free Remission on Combination Therapy (SPARE). NCT02177071. Clinicaltrials.gov."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24331"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.01.004"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1323867"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.15637","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.15637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T03:46:38Z","timestamp":1694058398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.15637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/apt.15637"],"URL":"https:\/\/doi.org\/10.1111\/apt.15637","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"2019-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}